The recent success of cancer immunotherapy approaches, namely immune checkpoint blockade and adoptive T cell transfer approaches, have instilled new hope on the use of the immune system to fight cancer. The Humanitas Cancer Center is currently testing many novel anti-cancer biological therapies in the context of Phase I, II and III clinical trials that not only block cancer cells but also boost the immune system of the host. The LTI profile the immune system of such patients in the course of therapy, disease progression and cure. We aim to identify immune correlates of response to therapy as well as new biological effects at the level of lymphocytes subpopulations.